Guidance regarding COVID-19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group

Lisanne C Verbruggen; Yuehan Wang; Saro H Armenian; Matthew J Ehrhardt; Helena J H van der Pal; Elvira C van Dalen; Jorrit W van As; Edit Bardi; Katja Baust; Claire Berger; Elio Castagnola; Katie A Devine; Judith Gebauer; Jordan Gilleland Marchak; Adam W Glaser; Andreas H Groll; Gabrielle M Haeusler; Jaap den Hartogh; Riccardo Haupt; Lars Hjorth; Miho Kato; Tomáš Kepák; Maria M W Rianne Koopman; Thorsten Langer; Miho Maeda; Gisela Michel; Monica Muraca; Paul C Nathan; Selina R van den Oever; Vesna Pavasovic; Satomi Sato; Fiona Schulte; Lillian Sung; Wim Tissing; Anne Uyttebroeck; Renée L Mulder; Claudia Kuehni; Roderick Skinner; Melissa M Hudson; Leontien C M Kremer

doi:10.1002/pbc.28702

Guidance regarding COVID-19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group

Pediatr Blood Cancer. 2020 Dec;67(12):e28702. doi: 10.1002/pbc.28702. Epub 2020 Sep 23.

Authors

Lisanne C Verbruggen¹, Yuehan Wang¹, Saro H Armenian², Matthew J Ehrhardt^{3

4}, Helena J H van der Pal¹, Elvira C van Dalen¹, Jorrit W van As⁵, Edit Bardi^{6

7}, Katja Baust⁸, Claire Berger^{9

10}, Elio Castagnola¹¹, Katie A Devine¹², Judith Gebauer¹³, Jordan Gilleland Marchak¹⁴, Adam W Glaser¹⁵, Andreas H Groll¹⁶, Gabrielle M Haeusler^{17

18

19}, Jaap den Hartogh²⁰, Riccardo Haupt²¹, Lars Hjorth²², Miho Kato²³, Tomáš Kepák²⁴, Maria M W Rianne Koopman¹, Thorsten Langer²⁵, Miho Maeda²⁶, Gisela Michel²⁷, Monica Muraca²⁸, Paul C Nathan²⁹, Selina R van den Oever¹, Vesna Pavasovic³⁰, Satomi Sato³¹, Fiona Schulte³², Lillian Sung³³, Wim Tissing^{1

34}, Anne Uyttebroeck³⁵, Renée L Mulder¹, Claudia Kuehni³⁶, Roderick Skinner³⁷, Melissa M Hudson^{3

4}, Leontien C M Kremer^{1

38}

Affiliations

¹ Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
² Department of Population Sciences, City of Hope National Medical Center, Duarte, California, USA.
³ Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
⁴ Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
⁵ Cochrane Childhood Cancer, Amsterdam, the Netherlands.
⁶ St Anna Childrens Hospital, Vienna, Austria.
⁷ Kepler University Clinic, Med Campus IV, Linz, Austria.
⁸ Department for Pediatric Hematology and Oncology, University Hospital Bonn, Bonn, Germany.
⁹ Department for Pediatric Hematology and Oncology CHU Nord, University Hospital Saint-Etienne, Saint-Priest en Jarez, France.
¹⁰ Epidemiology of Childhood and Adolescent Cancers, CRESS, INSERM, UMR 1153, Paris Descartes University, Villejuif, France.
¹¹ Infectious Diseases Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy.
¹² Rutgers Cancer Institute of New Jersey, The State University of New Jersey, New Brunswick, New Jersey, USA.
¹³ Institute for Endocrinology and Diabetes, University of Luebeck, Ratzeburger Allee 160, Luebeck, 23562, Germany.
¹⁴ Emory University School of Medicine, Aflac Cancer and Blood Disorders Center, Atlanta, Georgia, USA.
¹⁵ Department of Paediatric Oncology, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Medical Research, University of Leeds, Leeds, LS2 9JT, UK.
¹⁶ Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University Children's Hospital, Münster, Germany.
¹⁷ NHMRC National Centre for Infections in Cancer, Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
¹⁸ Department of Infectious Diseases, Peter MacCallum Cancer Centre and Royal Children's Hospital, Parkville, Victoria, Australia.
¹⁹ Murdoch Children's Research Institute, Parkville, Victoria, Australia.
²⁰ Dutch Childhood Cancer Parent Organization VOKK Netherlands, Department VOX Survivors, Nieuwegein, the Netherlands.
²¹ Epidemiology and Biostatistics Unit and DOPO clinic IRCCS Istituto Giannina Gaslini, Genova, Italy.
²² Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Pediatrics, Lund, Sweden.
²³ Department of Pediatric Hematology/Oncology, Okinawa Prefectural Nanbu Medical Center and Children's Medical Center, Okinawa, Japan.
²⁴ University Hospital Brno and St. Anna University Hospital/ICRC, Masaryk University, Brno, Czech Republic.
²⁵ University Hospital for Children and Adolescents, Pediatric Oncology and Hematology, Ratzeburger Allee 160, Luebeck, 23562, Germany.
²⁶ Department of Pediatrics, Nippon Medical School, Tokyo, Japan.
²⁷ Department of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.
²⁸ Epidemiology and Biostatistics Unit and DOPO Clinic IRCCS Istituto Giannina Gaslini, Genova, Italy.
²⁹ The Hospital for Sick Children, Toronto, Canada.
³⁰ Department of Malignant Haematology, Great Ormond Street Hospital for Children NHS Trust, London, UK.
³¹ St. Luke's International University, Tokyo, Japan.
³² Department of Oncology, Division of Psychosocial Oncology, University of Calgary, Calgary, AB, Canada.
³³ Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada.
³⁴ Department of Pediatric Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
³⁵ Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium.
³⁶ Childhood Cancer Registry (ChCR), Institute for Social and Preventive Medicine, University of Bern, Bern, Switzerland.
³⁷ Department of Paediatric and Adolescent Haematology/Oncology, Great North Children's Hospital, and Clinical and Translational Research Institute, Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK.
³⁸ Amsterdam University Medical Center, Department of Pediatrics, Amsterdam, the Netherlands.

Abstract

Childhood, adolescent, and young adult (CAYA) cancer survivors may be at risk for a severe course of COVID-19. Little is known about the clinical course of COVID-19 in CAYA cancer survivors, or if additional preventive measures are warranted. We established a working group within the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) to summarize existing evidence and worldwide recommendations regarding evidence about factors/conditions associated with risk for a severe course of COVID-19 in CAYA cancer survivors, and to develop a consensus statement to provide guidance for healthcare practitioners and CAYA cancer survivors regarding COVID-19.

Keywords: COVID-19; childhood adolescent and young adult (CAYA) cancer survivors; late effects of cancer treatment.

Publication types

Multicenter Study

MeSH terms

Adolescent
Adult
Betacoronavirus*
COVID-19
Cancer Survivors*
Child
Child, Preschool
Coronavirus Infections / epidemiology
Coronavirus Infections / prevention & control*
Coronavirus Infections / therapy*
Coronavirus Infections / transmission
Female
Humans
Male
Neoplasms / epidemiology
Neoplasms / therapy*
Pandemics / prevention & control*
Pneumonia, Viral / epidemiology
Pneumonia, Viral / prevention & control*
Pneumonia, Viral / therapy*
Pneumonia, Viral / transmission
Practice Guidelines as Topic
SARS-CoV-2
Young Adult